Clinical trials: Low-Grade Lymphoma
Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have…
- Trial name
- NCT00168727
- Testing
- ibritumomab tiuxetan (Zevalin®)
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Non-Hodgkin's Lymphoma, Lymphoma, B-cell
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade
- Trial name
- NCT00051025
- Testing
- ONTAK
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Lymphoma
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.
- Trial name
- NCT01609010
- Testing
- rituximab, interferon-a-2a
- Where
- 31 sites in Denmark, Norway and 1 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
- Trial name
- NCT01264822
- Testing
- Rabeprazole Sodium
- Where
- 42 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Eisai Co., Ltd.
Lymphoma, Non-Hodgkin
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab
This is a multi-center study for the long-term follow-up of surviving patients who are expected to complete or who have completed at least two years of follow-up after treatment with Iodine I 131 Tositumomab (BEXXAR) on Studies…
- Trial name
- NCT00240578
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Non-Hodgkin's Lymphoma
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent…
- Trial name
- NCT00044902
- Testing
- epratuzumab
- Sponsor
- Amgen
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
- Trial name
- NCT06708897
- Testing
- Lonitoclax (ZE50-0134)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.